

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2014

Reactivation of multiple viruses in patients with sepsis

Andrew H. Walton

Washington University School of Medicine in St. Louis

Jared T. Muenzer

Washington University School of Medicine in St. Louis

David Rasche

Washington University School of Medicine in St. Louis

Jonathan S. Boomer

Washington University School of Medicine in St. Louis

Bryan Sato

Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Walton, Andrew H.; Muenzer, Jared T.; Rasche, David; Boomer, Jonathan S.; Sato, Bryan; Brownstein, Bernard H.; Pachot, Alexandre; Brooks, Terrence L.; Deych, Elena; Shannon, William D.; Green, Jonathan M.; Storch, Gregory A.; and Hotchkiss, Richard S., "Reactivation of multiple viruses in patients with sepsis." PLoS One. 9, 6. e98819. (2014).

https://digitalcommons.wustl.edu/open_access_pubs/3199

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Andrew H. Walton, Jared T. Muenzer, David Rasche, Jonathan S. Boomer, Bryan Sato, Bernard H. Brownstein, Alexandre Pachot, Terrence L. Brooks, Elena Deych, William D. Shannon, Jonathan M. Green, Gregory A. Storch, and Richard S. Hotchkiss



Reactivation of Multiple Viruses in Patients with Sepsis

Andrew H. Walton¹, Jared T. Muenzer², David Rasche¹, Jonathan S. Boomer³, Bryan Sato⁴, Bernard H. Brownstein¹, Alexandre Pachot⁵, Terrence L. Brooks³, Elena Deych³, William D. Shannon³, Jonathan M. Green³, Gregory A. Storch², Richard S. Hotchkiss^{1*}

1 Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, United States of America, **2** Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United States of America, **3** Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America, **4** Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America, **5** Medical Diagnostic Discovery Department, BioMérieux Inc., Marcy l'Etoile, France

Abstract

A current controversy is whether patients with sepsis progress to an immunosuppressed state. We hypothesized that reactivation of latent viruses occurred with prolonged sepsis thereby providing evidence of clinically-relevant immunosuppression and potentially providing a means to serially-monitor patients' immune status. Secondly, if viral loads are markedly elevated, they may contribute to morbidity and mortality. This study determined if reactivation of herpesviruses, polyomaviruses, and the anellovirus TTV occurred in sepsis and correlated with severity. Serial whole blood and plasma samples from 560 critically-ill septic, 161 critically-ill non-septic, and 164 healthy age-matched patients were analyzed by quantitative-polymerase-chain-reaction for cytomegalovirus (CMV), Epstein-Barr (EBV), herpes-simplex (HSV), human herpes virus-6 (HHV-6), and TTV. Polyomaviruses BK and JC were quantitated in urine. Detectable virus was analyzed with respect to secondary fungal and opportunistic bacterial infections, ICU duration, severity of illness, and survival. Patients with protracted sepsis had markedly increased frequency of detectable virus. Cumulative viral DNA detection rates in blood were: CMV (24.2%), EBV (53.2%), HSV (14.1%), HHV-6 (10.4%), and TTV (77.5%). 42.7% of septic patients had presence of two or more viruses. The 50% detection rate for herpesviruses was 5–8 days after sepsis onset. A small subgroup of septic patients had markedly elevated viral loads ($>10^4$ – 10^6 DNA copies/ml blood) for CMV, EBV, and HSV. Excluding TTV, DNAemia was uncommon in critically-ill non-septic patients and in age-matched healthy controls. Compared to septic patients without DNAemia, septic patients with viremia had increased fungal and opportunistic bacterial infections. Patients with detectable CMV in plasma had higher 90-day mortality compared to CMV-negative patients; $p < 0.05$. Reactivation of latent viruses is common with prolonged sepsis, with frequencies similar to those occurring in transplant patients on immunosuppressive therapy and consistent with development of an immunosuppressive state. Whether reactivated latent viruses contribute to morbidity and mortality in sepsis remains unknown.

Citation: Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, et al. (2014) Reactivation of Multiple Viruses in Patients with Sepsis. PLoS ONE 9(6): e98819. doi:10.1371/journal.pone.0098819

Editor: Lyle L. Moldawer, University of Florida College of Medicine, United States of America

Received: April 10, 2014; **Accepted:** May 7, 2014; **Published:** June 11, 2014

Copyright: © 2014 Walton et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. The data contains identifying human information and is available upon request. Requests for the data may be sent to Dr. Richard Hotchkiss (hotch@wustl.edu).

Funding: This work received financial support from the following National Institutes of Health grants: GM 441181, GM 55194, GM09839, AI101530, and HL 104985. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Dr. Alexandre Pachot is an employee of Biomérieux. Biomérieux is trying to develop a method to follow the levels of various viruses in patient blood as an indicator of their immune status. Biomérieux provided no funding for the study and had no impact on writing up the study. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

* E-mail: hotch@wustl.edu

Introduction

Sepsis is the host's non-resolving inflammatory response to infection that leads to organ dysfunction [1,2]. A current controversial hypothesis postulates that if sepsis pursues a protracted course, it progresses from an initial primarily hyper-inflammatory phase to a predominantly immunosuppressive state [3–7]. Experimental therapeutic approaches in sepsis have almost exclusively focused on blocking early inflammation or host-pathogen interaction and failed [8–10]. Recently, immuno-adjuvant therapies that boost host immunity, e.g., GM-CSF and interferon- γ , have been successful in small clinical trials thereby supporting the concept that reversing immunosuppression in sepsis is a plausible strategy to improve outcome [11,12]. However, several issues have limited this approach including lack of

consensus that immunosuppression is a clinically important phenomenon [5,6,13]. Also, difficulty in identifying patients with impaired immunity as well as determining optimal timing for administration pose significant challenges to pursuing this approach [14]. While immuno-adjuvant therapies might improve sepsis survival if administered during the later immunosuppressive phase, these agents might worsen outcome if given during the early hyper-inflammatory phase [4,14]. Thus, a means to distinguish these two contrasting phases of sepsis is needed not only to verify the hypothesis that sepsis progresses to an immunosuppressive state but also to guide use of potential agents which boost immunity.

Latent viruses such as cytomegalovirus are normally held in abeyance by cellular and immune surveillance mechanisms which if impaired, for example by immunosuppressive medications, often

Table 1. Patient Characteristics.

		Septic	Critically-III Non-Septic	Healthy Controls
# Patients		560	160	165
Age	Median	63	63	64
	range[IQR]	52–74	53–76	60–72
Gender (%)	Male	305 (55)	81 (51)	81 (49)
	Female	255 (45)	79 (49)	84 (51)
Apache II *	median	18	5	
	range[IQR]	15–22	4–7	
SOFA**	median	7	2	
	range[IQR]	5–10	1–3	
Length of ICU Stay	median	11	2	
	range[IQR]	6–19	2–3	
Mortality (%)	survived	416 (74)	151 (94)	
	expired	144 (26)	9 (6)	
Admission ICU Diagnosis	Trauma		59	
	Post-operation (major surgery)		37	
	Neurologic events		40	
	Cardiovascular events		7	
	Miscellaneous		17	
Site of Infection	Pneumonia	284		
	Peritonitis	181		
	Surgical site and wound infection	71		
	Intravascular catheter infection	14		
	Urinary tract infection	10		

*Apache II, "Acute Physiology and Chronic Health Evaluation II" at ICU admission.

**SOFA, "Sequential Organ Failure Assessment" at ICU admission.

doi:10.1371/journal.pone.0098819.t001

result in viral reactivation, replication, and virally-mediated tissue injury [15–20]. Sepsis impairs innate and adaptive immunity by multiple mechanisms including apoptosis-induced depletion of immune effector cells and induction of T-cell exhaustion thereby possibly predisposing to viral reactivation and dissemination [21–23].

Although viral reactivation has been documented in sepsis, studies have generally been limited in scope, focusing on CMV viremia or HSV-1 pneumonitis [15,18,20,24–28]. No comprehensive study of the herpes or polyomavirus family has been conducted in sepsis. Demonstration that widespread reactivation of latent herpes and polyomavirus occurs in sepsis has several important implications. First, it would provide strong evidence that sepsis results in functional immunosuppression and may provide a means to track patient immunocompetence during the disorder. Secondly, depending upon the level of viremia, reactivated viruses may contribute to morbidity and mortality in the disorder. We also investigated TTV, an anellovirus previously shown to be present in up to 40–50% of healthy adults [29–33]. Recent studies in patients with liver and stem cell transplantation, patients with HIV, and patients with chronic renal failure indicate that the magnitude of TTV viremia reflects patient immunocompetence and that TTV viral load is useful as a surrogate marker of the robustness of immunity [30–33].

Methods: (in addition, see Supporting Information)

Inclusion criteria

Septic patients. Non-immunocompromised patients treated in surgical/medical ICUs (2009–2013) were identified prospectively. Sepsis was defined as a microbiologically-proven, clinically-proven, or suspected infection and presence of systemic inflammatory response syndrome [10]. Patients were followed through hospital discharge or 90 days after sepsis onset. Mortality status at 90 days was available for >95% of study subjects.

Critically-ill non-septic patients (CINS) and healthy-control patients. Non-septic, non-immunocompromised patients being treated in surgical/medical ICUs were one comparison group. A second group consisted of age-matched, ambulatory, pre-operative elective-surgery patients (American Society of Anesthesiology [ASA] class 1–3).

Exclusion criteria

Patient exclusion criteria included: HIV-1, organ transplantation, high-dose corticosteroids (≥ 300 mgs/day hydrocortisone) or other immunosuppressive medications, viral hepatitis, and autoimmune diseases.

Table 2. Frequency of Viral DNA in Septic and Control Patients.

Virus	Septic	Critically-Ill Non-Septic	Healthy Controls
	No. positive [†] /No. tested (%)		
CMV*	86/356 (24.2)	1/89 (1.1)	0/165 (0)
EBV	287/539 (53.2)	18/149 (12.1)	6/165 (3.6)
HSV	76/538 (14.1)	2/150 (1.3)	0/165 (0)
HHV-6	56/539 (10.4)	1/150 (0.7)	7/165 (4.2)
TTV [‡]	179/231 (77.5)	33/55 (63.6)	98/165 (60.1)
JC**	85/238 (35.7)	10/42 (23.8)	
BK**	35/237 (14.3)	4/42 (9.5)	
Any Virus	432/560 (77.1)	62/161 (38.5)	104/165 (63.0)
>1 Virus	239/560 (42.7)	9/161 (5.6)	9/165 (5.5)

[†]Except where indicated, No. positive reflects the number of patients who tested positive in either whole blood or plasma or both. No. tested represents the total number of patients tested.

*Results are from CMV seropositive patients only.

[‡]Tested in plasma only.

**Tested in urine.

doi:10.1371/journal.pone.0098819.t002

Blood and Urine Collection

Analyses were performed on residual blood remaining after clinical hematologic testing was performed (Septic and CINS), or blood obtained from ambulatory volunteers prior to elective surgery (Healthy Control). Blood was retrieved daily starting within 24–72 hrs. of ICU admission. Whole blood and plasma were stored at -80°C . For detection of BK and JC, urine was typically obtained twice/week. Quantitative-PCR (qPCR) was performed 2–3 times/week.

CMV Serologic testing

IgG antibodies to CMV were quantitated by ELISA to identify individuals with prior CMV exposure.

Sample preparation and viral DNA detection

DNA was extracted using the NucliSens-EasyMag-extractor (BioMérieux) and assayed for viruses by qPCR using protocols from the Clinical Virology Laboratory at St Louis Children's Hospital (except HHV-6 and TTV) and as previously described [34–39]. Briefly 5 μL of sample was used per reaction, and assays

were performed on either an ABI 7500 Fast system (Applied Biosystems), or a LightCycler II (Roche). (See Table S1. for details regarding lower limit of quantitation for each virus and interassay coefficient-of-variation).

Statistical analysis

Data were analyzed using SAS-Statistical Software. Kaplan-Meier analyses were used for mortality, ICU length-of-stay, and secondary infection rates. Chi-square and *t*-tests were used for categorical and continuous variables.

Human Studies Human Studies

The study was approved by the Washington University Human Research Protection Office. Patient consent was obtained for venipuncture and chart review from pre-operative elective surgery patients. Oral consent was documented by having the patient sign the study consent form which was then placed in the patient chart with an additional copy kept with the research nurse coordinator. For septic and critically-ill non-septic patients, a waiver of consent was granted for obtaining excess clinical “waste” laboratory blood

Table 3. Frequency of Viral DNA in Blood and Plasma Individually.

Virus	Septic		Critically-Ill Non-Septic		Healthy Controls	
	Blood	Plasma	Blood	Plasma	Blood	Plasma
	No. positive/No. tested (%)					
CMV*	71/345 (20.6)	33/148 (22.3)	1/79 (1.27)	0/29 (0)	0/164 (0)	0/165 (0)
EBV	275/522 (52.7)	75/235 (31.9)	15/127 (11.8)	3/55 (5.45)	5/164 (3.1)	1/165 (0.61)
HSV	65/521 (12.5)	42/235 (17.9)	2/128 (1.56)	0/54 (0)	0/164 (0)	0/164 (0)
HHV-6	35/522 (6.9)	30/235 (12.8)	1/128 (0.78)	0/55 (0)	5/164 (3.1)	6/165 (3.64)
TTV		179/231 (77.5)		35/55 (63.6)		98/165 (60.1)
Any Virus	312/522 (59.8)	204/235 (86.8)	19/128 (14.8)	36/55 (65.5)	10/164 (6.1)	102/165 (61.8)
>1 Virus	106/522 (20.3)	106/522 (20.3)	0/128 (0)	2/55 (3.64)	0/164 (0)	5/165 (3.03)

*Results are from CMV seropositive patients only. No. positive represents the number of patients who tested positive in Blood or in Plasma separately. No. tested represents the total number of patients tested.

doi:10.1371/journal.pone.0098819.t003

Table 4. Viral Loads in Blood, Plasma, and Urine.

	Septic		Critically Ill										Healthy Controls									
	Blood																					
	CMV	EBV	HSV	HHV-6	TTV	CMV	EBV	CMV	EBV	HSV	HHV-6	TTV	CMV	EBV	CMV	EBV	HSV	HHV-6	TTV			
GeoMean	6409.1	6067.7	6144.2	5863.1	3.65E+05	3091	5631	3091	5631	4000	3000	1.41E+05	N/A	4000	N/A	4000	N/A	1.85E+07	63618			
GeoSEM	1.21	1.06	1.19	1.39	1.2	1	1.29	1	1.29	1	1	1.5	N/A	1	N/A	1	N/A	10.6	1.44			
Median	2326.5	4000	4000	3000	2.71E+05	3091	4000	3091	4000	4000	3000	2.18E+05	N/A	4000	N/A	4000	N/A	2.39E+07	62870			
Max	554917	1.00E+07	4.29E+07	1.33E+07	5.30E+09	3091	1.44E+05	3091	1.44E+05	4000	3000	3.24E+07	N/A	4000	N/A	4000	N/A	1.92E+09	2.18E+07			
Min	2000	4000	4000	3000	2000	3091	4000	3091	4000	4000	3000	2000	N/A	4000	N/A	4000	N/A	3000	2000			
Plasma																						
CMV	10896.5	4000	14342.5	4491.3	63946.9	N/A	4000	N/A	4000	N/A	N/A	27047	N/A	4000	N/A	4000	N/A	1.95E+06	20697			
GeoSEM	1.41	1	1.25	1.31	1.25	N/A	1	N/A	1	N/A	N/A	1.37	N/A	1	N/A	1	N/A	5.16	1.26			
Median	3243.4	4000	10640	3000	33504.2	N/A	4000	N/A	4000	N/A	N/A	33248	N/A	4000	N/A	4000	N/A	1.73E+06	11255			
Max	435789	4000	1.16E+06	1.41E+06	8.00E+09	N/A	4000	N/A	4000	N/A	N/A	1.50E+06	N/A	4000	N/A	4000	N/A	1.58E+08	6.50E+06			
Min	2000	4000	4000	3000	2000	N/A	4000	N/A	4000	N/A	N/A	2000	N/A	4000	N/A	4000	N/A	3000	2000			
Urine																						
JC						JC	BK															
GeoMean	2.32E+06	62441						9.67E+05	17931													
GeoSEM	1.5	1.59						2.89	2.61													
Median	2.57E+06	31121						8.84E+05	16706													
Max	4.41E+09	7.52E+07						3.56E+08	2.20E+05													
Min	4000	4000						9620	4000													

doi:10.1371/journal.pone.0098819.t004




Figure 1. Viral levels in septic and control patients. The maximum viral load for each patient is displayed. (Figure 1A) Only data from septic patients are displayed for CMV, EBV, HSV, and HHV-6 because viral levels in control patients for these viruses were at or below the limit of quantitation. (Figure 1B) For JC and BK, data are from urine samples of septic and critically-ill non-septic (CINS) patients. (Figure 1C) The maximum viral load for TTV is displayed for septic, CINS, and healthy control pre-operative elective-surgery (HC) patients. The horizontal line in each graph represents the geometric mean for the virus level.

doi:10.1371/journal.pone.0098819.g001

(that was slated to be discarded) and for review of their relevant hospital records because these procedures were considered to represent minimum risk to the patients.

Results

Demographic data

560 septic, 160 CINS, and 165 healthy control patients were included (Table 1). The 560 septic patients included 31 patients originally classified as CINS who developed sepsis during their ICU admission and were transferred into the septic category. Median duration of ICU stay was 11 days (range 2–127) and 2 days (range 1–12) for septic and CINS patients respectively. The number of blood samples for septic and CINS patients ranged from 1–27 (mean 3.1) and 1–2 (mean 1.1) respectively. A single

blood sample was obtained prior to surgery for the healthy control patients.

Cumulative detection rates and levels of herpes family viruses

CMV. 70.2% of patients (septic and controls) were CMV seropositive within 2–4 days of ICU admission, indicative of prior infection. With one exception, detection of CMV by PCR occurred only in patients who were CMV seropositive. 24.2% of septic CMV seropositive patients had CMV detected with geometric mean (geomean) levels of 6,409 copies/ml whole blood and 10,896 copies/ml plasma (Figure 1, Tables 2–4). CMV was detected by PCR in one CINS patient and in no healthy control patients (Table 2).

Blood




Figure 2. Correlation of viral loads among the individual viruses. Populations were established based upon viral DNA loads; each of these populations was examined for presence or absence of other viruses. The number of patients in each of the groups is defined as the following: *Negative* = no detectable virus, *Low* = less than lower limit of quantitation (lloq), and *High* = greater than lloq. The negative, low, and high values for CMV are N=274, 34, and 37 septic patients, respectively. Negative, low, and high values for EBV are N=247, 213, and 61 septic patients, respectively; for HSV comparable values are N=465, 38, 18, septic patients, respectively). For HHV-6, Negative=no detectable virus (n=485 patients), Positive=detectable virus (n=36 patients); *p<0.05, **p<0.01, ***p<0.001. These results show that as the blood viral load of one particular virus increases, there is a corresponding increase in the prevalence of the other herpes family members. doi:10.1371/journal.pone.0098819.g002

EBV. EBV was detected in blood samples from 53.2% of septic patients (Tables 2–4). Fifty-two septic patients (18.9%) had levels $\geq 10,000$ copies/ml whole blood, a level that is considered an indication for reducing immunosuppression in solid-organ transplant recipients at our institution (Figure 1, Table 4). EBV was detected in 12.1% and 3.6% of CINS and healthy control patients respectively.

HSV. HSV was detected in 14.1% of septic patients with geomean equaling 6,144 copies/ml whole blood and 14,342 copies/ml plasma (Tables 2–4). HSV was detected in blood of 1.5% of CINS patients. No healthy control patients had HSV viremia.

HHV-6. HHV-6 was detected in 10.4% of septic patients (Tables 2–4). One CINS and 6 (3.3%) healthy control patients were positive. HHV-6 levels were generally at or below the lower limit of quantitation of the qPCR assay (3,000 copies/ml blood).

Cumulative detection rate and levels of TTV

TTV was detected in plasma of 77.5% of septic patients with geomean equaling 64,000 copies/ml (Tables 2–4). TTV was detected in 63.6% and 60.1% of CINS and healthy control patients respectively. Geomean TTV levels were 27,000/ml and

21,000/ml in plasma of CINS and healthy control patients respectively.

Urine BK and JC detection rates and levels

JC was detected in urine of 35.7% of septic patients with geomean level of 2.3×10^6 copies/ml (Table 2). JC was detected in 23.8% of CINS patients with geomean level of 9.7×10^5 copies/ml. BK was detected in urine of 14.3% and 9.5% of septic and CINS patients respectively. BK geomean values were 62,441 copies/ml and 17,931 copies/ml in septic and CINS patients (Table 4).

Septic patients have multiple viruses with corresponding high viral titers

Overall, 42.7% of septic patients had two or more viruses detected during their illness (Table 2). This 42% may underestimate the frequency because not all patients were tested for all viruses. In a subgroup of 209 patients who were tested for all viruses, 54.1% were positive for multiple viruses including 27.8% positive for 2 viruses, 17.2% for 3 viruses, 7.7% for 4 viruses, 3.8% for 5 viruses, and 0.5% for 6 viruses. We also correlated the impact of the load of each of the viruses upon the prevalence of other viruses. In blood samples, the magnitude of the viral load of one




Figure 3. Peak viral detection rate and time course of viral detection. The percentage of patients who tested positive in blood for particular viruses during the course of sepsis (limited to 30 days) is displayed in two formats. Day 0 represents the day that the patient fulfilled sepsis criteria [32]. *Figure 3A* represents all septic patients positive for viral reactivation divided by the total number of septic patients who were tested on or before the same day. *Figure 3B* represents only those septic patients who were negative for the particular viruses and who ultimately became positive during their septic course. The % represents the increase in the number of septic patients who convert from virus negative to virus positive status. *TTV was tested only in plasma (see Methods S1).
 doi:10.1371/journal.pone.0098819.g003

herpesvirus often correlated with increased prevalence of other herpesviruses (e.g. it was more common for patients with high CMV loads to have positive EBV tests than it was for patients who had low CMV loads or negative CMV tests), Figure 2. This correlation tended to occur in plasma as well but was not as prominent (Figure S1). This relationship did not hold between the herpes- and polyoma-viruses, i.e. there was no significant relationship between the load of any of the herpesviruses and prevalence of either polyomavirus, and vice versa (data not shown).

Time course of viral detection

During sepsis, virus detection rate increased for all viruses with ICU duration (Figure 3). The rapidity at which septic patients who were virus negative at study entry and who converted to virus positive status during their illness differed for various viruses (Figure 3B). The fastest conversion rate occurred for TTV with 50% and 75% detection rates occurring at days 3 and 6 after sepsis onset respectively. Among herpes viruses, the most rapid increase in detection rate (conversion from negative to positive viremia)

occurred for EBV with 50% and 75% detection rates of 5 and 7 days respectively. CMV had the slowest rise with 50% and 75% detection rates occurring at days 8 and 13 respectively. The 50% and 75% conversion rates for HSV were 7 and 10 days respectively while those for HHV-6 were 7 and 11 days respectively. Time course for detection of urine BK and JC virus is depicted in Figure S2.

Correlation of viremia with clinical and laboratory parameters

Secondary infections. Impaired immunity in septic patients is frequently manifest by infections with fungal or relatively non-virulent “opportunistic” type bacterial organisms [40,41]. We prospectively selected *Acinetobacter*, *Stenotrophomonas*, and *Enterococcus* as representative of “opportunistic” bacteria in patients with sepsis; these relatively weakly virulent pathogens are common causes of secondary infection in our ICUs [41]. Septic patients who had detectable CMV in either blood or plasma and septic patients who had EBV detectable in plasma had increased risk of fungal infections independent of length-of-stay or duration of sepsis, Figure 4 and Figure S3; ($p < 0.001$ for CMV and $p < 0.05$ for EBV). For both viruses, the relationship was stronger for detection of virus in plasma than whole blood. These relationships with fungal infection were not present for the other viruses examined. Patients who had detectable HSV in blood had increased risk of developing opportunistic bacterial infections which was independent of length-of-stay, Figure 4, ($p < 0.05$). A similar trend was also apparent for detection of HSV in plasma but not for any other virus.

ICU duration and severity of illness. Average ICU length-of-stay was increased in septic viremic versus non-viremic patients, Figure 5. Patient microbiologic data and white blood cell counts are shown in Table 5. For CMV and HSV, the number of ICU days was approximately doubled in patients who were viral positive versus viral negative. No effect of urine BK or JC was observed on length-of-stay. Septic patients with CMV viremia in blood had increased APACHE-II scores compared to CMV negative Table 6, $p < 0.01$. Viremia with CMV, EBV, HSV, and HHV-6 was associated with higher SOFA scores, Table 6, $p < 0.01$.

Effect of viral reactivation on mortality in sepsis. Septic patients with detectable CMV in plasma had increased 90-day mortality compared to CMV negative patients, Figure 6; $p \leq 0.05$. The increased mortality with CMV had a stepwise increase in mortality with increased viral levels, Figure 7; though this was not statistically significant. Compared to septic patients who were TTV negative, there was a trend for increased mortality in septic patients who had the highest quartile of TTV viral load, Figure 7. Surprisingly, septic patients who were EBV positive in blood (but not plasma) had lower 90-day mortality, Figure 6; $p < 0.05$. The protective effect of EBV tended to lessen as viral load increased in whole blood, Figure 8.

Discussion

A remarkable finding in the present study is the high prevalence of viral DNA in blood of septic patients. Previous studies which investigated viral reactivation in sepsis were generally focused on CMV or, much less commonly, HSV [15,20,24–28,42–44]. This is the first study to examine the impact of sepsis on multiple families of viruses. Detection of herpes viruses (CMV, EBV, HSV-1, and HHV-6), polyomaviruses (JC and BK), and anellovirus (TTV) occurred with high frequency in sepsis (Tables 2–4). These increased rates of viral detection are particularly striking when




Figure 4. Impact of viral reactivation on fungal and opportunistic bacterial infections. Septic patients with CMV detected in either blood or plasma had increased fungal infections compared to CMV negative patients; only results for plasma are shown and are significant, $p < 0.001$. Similarly, patients who had EBV detected in blood had increased fungal infections compared to viral negative patients, $p = 0.05$. Patients who were HSV positive in blood had increased opportunistic bacterial infections due to *Stenotrophomonas*, *Acinetobacter*, or *Enterococcus* compared to viral negative patients, $p < 0.05$. Censored subject (vertical hash marks) represent patients who were either discharged from the ICU or who died without events. Analysis was performed using all events but plot was truncated at 60 days for clarity. N = 35 patients with fungal infections, n = 86 patients with *Stenotrophomonas*, *Acinetobacter*, or *Enterococcus* infections.
doi:10.1371/journal.pone.0098819.g004




Figure 5. Patients with viral reactivation have increased ICU length of stays. The average number of days spent in the ICU for septic patients with versus without viremia was determined. Septic patients who were positive for CMV, EBV, TTV, HSV, and HHV-6 had longer ICU stays compared to comparable patients who were viral negative. There was no impact of urine JC or BK positivity on ICU length of stay. Values were compared by student's *t* test. doi:10.1371/journal.pone.0098819.g005

compared to results in non-septic patients and healthy-control patients. The fact that 42.7% of septic patients had viremia with multiple viruses as well as the magnitude of viral loads (Figure 1) provides strong evidence that host immunity is impaired in sepsis. Potential mechanisms of immunosuppression in sepsis include T-cell exhaustion, apoptotic depletion of CD4 and CD8 T-cells, myeloid-derived suppressor cells, and increased T-regulatory cells, all of which might contribute to viral reactivation [4,23,45,46]. Importantly, EBV, CMV, and HHV-6 detection rates for septic patients in this study are similar to those reported in stem-cell and organ transplant patients [47–50]. For example, a study of solid organ transplant recipients reported detection rates in blood of 56.3% for EBV, 13.7% for HHV-6, 12.2% for BK and 4.9% for JC [47]. Thus, viral detection in septic patients is comparable to that in transplant patients who are pharmacologically immunosuppressed, providing further support that our findings are indicative of clinically-relevant immunosuppression.

The 24.2% incidence of CMV reactivation in sepsis in the present study is similar to other sepsis studies [15,24,25,44,51]. Although HSV pneumonitis occurs in sepsis [20,28,52], the incidence of HSV viremia in sepsis has (to our knowledge) not

been previously reported. One study noted a >50% incidence of HHV-6A in critically-ill patients but this study was not confined to septic patients and the high percentage of HHV-6A reactivation seems incongruous with their other study finding of absence of CMV reactivation in their same patients [53]. The incidences of EBV, TTV, JC, and BK have not previously been reported in septic patients and therefore represent an important independent contribution to the literature.

Detection of the various viruses in the present study presumably represents viral reactivation. Almost all adults have been previously infected with HHV-6 and ~90% of adults have been previously infected with EBV [16,49]. The seroprevalences for HSV-1 and HSV-2 are 58% and 17% respectively [54] while those for JC and BK are ~70–80% and 60–70% respectively [17,19,55]. Therefore, it is likely that viral detection in the setting of sepsis is not due to primary infection but rather to viral reactivation. The precise mechanisms that lead to reactivation of latent viruses are not completely established, and indeed may differ between the different viruses. Pro-inflammatory cytokines, hypoxia, cell injury, and other stress-related mechanisms can induce viral reactivation and are commonly present in sepsis [56,57]. Thus, in addition to impaired immune surveillance, the initial hyper-inflammatory septic phase likely provides the stimulus which precipitates viral reactivation. However, the persistence and degree of elevated viral levels suggests that immune function is insufficient to effectively clear the viruses, strongly suggesting immune dysfunction. Most viruses were detected at high levels in plasma as well as blood (Table 2) and this finding is considered indicative of active viral replication [58]. Thus, while stress-induced mechanisms might initiate viral reactivation in sepsis, the predominant driving force for the extent, persistence, and degree of viral reactivation in most septic patients is most likely to be immune dysfunction. The degree and magnitude of viral loads is also consistent with impaired immunity in septic patients (see discussion below for EBV and TTV viral loads and immunosuppression).

EBV blood level is used as a surrogate marker of immunosuppression in transplant patients [49,59,60]. Fifty-two septic patients had EBV levels $\geq 10,000$ copies/ml of whole blood, a level that some transplant clinicians consider to represent excessive immunosuppression and therefore advise reduction in anti-rejection medications [60]. Previous studies have also shown correlation between circulating TTV levels and immunocompetence [29–31,61]. Unlike herpes viruses, TTV is not thought to enter latency

Table 5. Microbiology and Blood Cell Counts.

		Septic	Critically-ill Non-septic	Healthy Controls
Microbiology	Gram Negative	389		
	Gram Positive	323		
	Fungae	39		
White blood cell count (K/mm ³)	median	13.1	8.1	6.4
	range (IQR)	10.3–18.9	6.7–9.2	5.5–7.7
Absolute Lymphocytes K/mm ³	median	0.9	1.1	1.8
	range (IQR)	0.6–1.3	0.7–1.6	1.4–2.3
Absolute Monocytes K/mm ³	median	0.7	0.6	0.5
	range (IQR)	0.4–1.1	0.4–0.8	0.4–0.6
Absolute Polymorphonuclear K/mm ³	median	11.8	6	4.1
	range (IQR)	8.5–16.7	5.0–7.4	3.2–5.5

doi:10.1371/journal.pone.0098819.t005

Table 6. Correlation of Viral Positivity and Severity of Illness.

Virus	Mean [†] APACHE II (S.E.M.)		P-value	Mean [†] SOFA (S.E.M.)		P-value
	Virus Positive	Virus Negative		Virus Positive	Virus Negative	
CMV*	18.2 (0.58)	16.3 (0.39)	0.002	9.5 (0.41)	8.3 (0.20)	<0.01
EBV	17.2 (0.26)	17.4 (0.33)	0.687	8.9 (0.20)	8.0 (0.20)	<0.01
HSV	17.4 (0.49)	17.3 (0.23)	0.346	9.8 (0.42)	8.3 (0.15)	<0.001
HHV-6	18.4 (0.77)	17.2 (0.22)	0.145	9.8 (0.42)	8.3 (0.14)	<0.001
TTV	16.7 (0.26)	15.9 (0.44)	0.94	8.5 (0.19)	8.2 (0.26)	0.264
JC	16.3 (0.49)	16.6 (0.44)	0.783	7.3 (0.35)	7.4 (0.28)	0.963
BK	15.4 (0.60)	16.6 (0.37)	0.247	7.2 (0.48)	7.4 (0.24)	0.897

[†]Mean value represents mean of all patients' average APACHE II or SOFA score for the duration of their ICU stay.

*Represents CMV seropositive patients only.

doi:10.1371/journal.pone.0098819.t006

but rather to actively replicate at low levels and is present in plasma in ~50% of healthy adults without known pathologic effects [29–33]. Previous studies reported that elevated TTV viral loads occur more frequently in hemodialysis patients, diabetics, and HIV-infected patients with low CD4 counts than in healthy individuals or HIV-infected patients with CD4 counts >500/mm³ [29–33]. Three studies have reported that TTV viremia increases with the degree of immunosuppressive therapy in patients with organ transplantation and suggested that the magnitude of TTV viremia is indicative of the robustness of the immune system [31–33]. The high prevalence (76.4%) and viral load of TTV in septic patients likely reflects their immunosuppression.

A critical question which is *not* answered by the present study is whether the increased viral reactivation in sepsis is merely a marker of impaired immunity or contributes to sepsis morbidity/mortality. A subgroup of septic patients had extremely high levels of CMV and/or EBV (Figure 1) which are frequently associated with pathological effects. A current hypothesis is that CMV and HSV reactivation amplify sepsis-induced lung and systemic inflammation thereby contributing to multi-organ failure [15,61,62]. Additionally, chronic viral infections lead to T cell exhaustion and impaired immunity [63], and a recent postmortem study of septic patients demonstrated findings highly consistent with T cell exhaustion [23]. Thus, viral reactivation in sepsis could

lead to T cell exhaustion which further impairs host immunity leading to additional viral reactivation. Septic patients who had viral reactivation had increased infections with organisms that generally do not infect patients with competent immune systems, e.g. *Candida albicans*, *Stenotrophomonas*, *Acinetobacter*, *Enterococcus* (Figure 4) [40,41]. While this commensal fungus and these bacteria are generally considered opportunistic bacteria, they may enter the bloodstream through barrier breakdown. Whether the increased propensity for infections with relatively weakly pathogenic organisms is a result of viral-mediated effects to impair immunity or whether viral reactivation occurs more readily in more profoundly immunosuppressed septic patients is unknown.

A surprising finding is the decreased mortality in septic patients with EBV viremia in blood (but not plasma) compared to EBV-negative patients (Figure 6). A potential explanation for this seemingly paradoxical finding is provided by studies showing that mice with low level gammaherpes-virus-68 infection (a murine virus genetically similar to human EBV) have improved survival and/or decreased microbial burden in bacterial sepsis due to *L. monocytogenes* and *T. pestis* [64]. In that animal model, EBV infection protected by activating NK cells to produce IFN- γ , an essential factor for viral control. Significantly, EBV in plasma did not display a survival benefit and was associated with increased fungal infections. These findings may signal a fundamental difference




Figure 6. Impact of CMV and EBV on sepsis mortality. Septic patients who were CMV positive in plasma had increased 90 day mortality compared to CMV negative patients, $p < 0.05$. Surprisingly, patients who were EBV positive in whole blood (but not plasma) had decreased 90 day mortality compared to EBV negative patients, $p < 0.001$. Data analyzed by Kaplan Meier.

doi:10.1371/journal.pone.0098819.g006




Figure 7. Impact of CMV and TTV viral loads on sepsis mortality. The relationship between CMV and TTV viral load in blood and 90 day mortality is displayed. There was a non-statistically significant increase in mortality due to sepsis with increasing CMV viral levels in blood. (Note that septic patients who were CMV positive in plasma did have increased mortality compared to CMV negative patients - see Figure 6). Compared to septic patients who were TTV negative, patients with the highest quartile viral load for TTV (Q4) had a trend toward increased 90 day mortality ($p=0.06$).
doi:10.1371/journal.pone.0098819.g007

between patients with low and high levels of EBV in blood. We speculate that early reactivation of EBV in sepsis identifies patients who mount a more vigorous response to the pathogens. However, persistent EBV at high levels is likely detrimental to the host.

There are several significant implications of the present study. First, the current results highlight a degree of immunosuppression in septic patient that is on par with pharmacologically-induced immunosuppression in organ transplant patients [47–50]. Secondly, an intriguing idea is that serial quantitation of circulating viral load for a panel of viruses may be useful as a biomarker of host immunity in sepsis. This concept of tracking changes in viral load is similar to the approach used to guide dosing of immunosuppressive medications in some organ transplant recipients [47–50]. Besides the viruses quantitated in the present study, HHV-7, adenovirus, parvovirus B19, and human bocavirus are other candidates that might provide additional information regarding the status of host immunity [64,65,66]. Finally, these results provide a strong rationale for future and ongoing clinical trials of agents that boost host immunity in patients who have entered the immunosuppressive phase of sepsis [11,12].

A limitation to this study is the inability to make direct comparisons between septic and control groups. The ICU length-of-stay for CINS was considerably shorter than for septic patients

because these patients tended to be more clinically stable and were transferred out of the ICU. Consequently, more serial-samples were obtained from septic versus CINS patients, undoubtedly contributing to the increased detection of viral DNA in sepsis. Additionally, severity of illness in septic patients is invariably higher as a consequence of sepsis-induced multi-organ dysfunction. These issues make direct statistical comparisons between septic and control patients invalid. However, 31 CINS patients who became septic during their ICU stay were included and these patients had viral reactivation typical of the septic group at large following sepsis onset. It is possible that viral reactivation may not be related simply to sepsis but could extend to all critically-ill patients with similar severity of illness and length-of-stay. In this regard, EBV reactivation was higher in CINS patients versus healthy controls, $p<0.003$.

Conclusions

In conclusion, reactivation of latent viruses is extremely common in patients with prolonged sepsis and is consistent with development of immunosuppression. Whether reactivated viruses represent an epiphenomenon or contribute to morbidity and mortality remains unknown and should be addressed because of




Figure 8. Effect of EBV load on survival. EBV in whole blood (but not plasma) was associated with a decrease in sepsis mortality. This protective effect of EBV DNAemia tended to lessen with increased viral burden although the effect was not statistically significant.
doi:10.1371/journal.pone.0098819.g008

their potential impact on morbidity and mortality. Serially tracking of viral load for a panel of latent viruses might be useful as indicators of the state of host immunity.

Supporting Information

Figure S1 Effect of viral load on prevalence of other viruses. This Figure corresponds to Figure 2 displaying results for plasma as opposed to blood. Populations were established based upon viral DNA loads; each of these populations was examined for presence or absence of other viruses. Groups are defined as Negative = no detectable virus; Low = less than the median DNA load; High = greater than or equal to median DNA load. Negative, low, and high values for CMV (median = 3,243, n = 115, 16, 17 respectively) and HSV (median = 10,640, n = 193, 21, 21 respectively). For EBV and HHV-6, Negative = no detectable virus (n = 146 and n = 205 respectively), Positive = detectable virus (n = 72 and n = 30 respectively). For TTV, Negative = no detectable virus (n = 52), Q1 = first quartile (<5,881 copies/mL, n = 45), Q2 = second quartile (between 5,881 and 33,504 copies/mL, n = 45), Q3 = third quartile (between 33,717 and 299,609 copies/mL, n = 45), and Q4 = fourth quartile (>299,609 copies/mL, n = 44). Although the correlation is not as striking as in blood (Figure 2), there is a correlation between the viruses such that as the level of one virus increases, there tends to be a concomitant increase in the prevalence of other herpes viruses. (TIF)

Figure S2 Peak detection rate and time course of detection for BK and JC. The percentage of patients who tested positive in urine JC or BK virus during the course of sepsis (limited to 30 days) is displayed in two formats. Day 0 represents the day that the patient fulfilled sepsis criteria. *Figure S2A* represents all septic patients positive for viral reactivation divided by the total number of septic patients who were tested on or before the same day. The plot starts at day 3 because of skewing of display by small patient numbers. *Figure S2B* represents only those septic patients who were negative for the particular viruses and who ultimately became positive during their septic course. The %

represents the increase in the number of septic patients who convert from virus negative to virus positive status. (TIF)

Figure S3 Percentage of fungal infections in septic patients. The percentage of hospital-acquired fungal infections at day 60 were quantitated for septic patients with or without CMV and EBV viral reactivation. Note that patients whose blood was positive for CMV or EBV had increased incidence of fungal infections as depicted in the vertical axis. (The data for the relationship between fungal and opportunistic bacterial infections for patients who were positive for CMV or EBV in plasma is shown in Figure 4. Censored subject (vertical hash marks) represent patients who were either discharged from the ICU or who died without events. Analysis was performed using all events but plot was truncated at 60 days for clarity. (TIF)

Table S1 qPCR assays. Characteristics of virus qPCR assays, including LLOQs (Lower Limits of Quantitation), average CVs and references. (CSV)

Methods S1 Supporting materials and methods. Expands upon inclusion/exclusion criteria, virus qPCR assays and analysis criteria. (DOCX)

Acknowledgments

We gratefully acknowledge the lab of Randall T Hayden (Dept of Pathology, St Jude Children's Research Hospital) for development of the HHV-6 assay.

Author Contributions

Conceived and designed the experiments: AHW JTM JSB BHB AP WDS JMG GAS RSH. Performed the experiments: AHW JTM DR JSB BS. Analyzed the data: AHW JTM DR BS TLB ED WDS. Contributed to the writing of the manuscript: AHW BS JMG GAS RSH.

References

- Vincent JL, Opal SM, Marshall JC, Tracey KJ (2013) Sepsis definitions: time for change. *Lancet* 381: 774–775.
- Angus DC, van der Poll T (2013) Severe sepsis and septic shock. *N Engl J Med* 369: 840–851.
- Munford RS, Pugin J (2001) Normal responses to injury prevent systemic inflammation and can be immunosuppressive. *Am J Respir Crit Care Med* 163: 316–321.
- Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. *N Engl J Med* 348: 138–150.
- Cohen J, Opal S, Calandra T (2012) Sepsis studies need new direction. *Lancet Infect Dis* 12: 503–505.
- Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, et al. (2011) A genomic storm in critically injured humans. *J Exp Med* 208: 2581–2590.
- Hotchkiss RS, Monneret G, Payen D (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. *Lancet Infect Dis* 13: 260–268.
- Angus DC (2011) The search for effective therapy for sepsis: back to the drawing board? *JAMA* 306: 2614–2615.
- Dolgin E (2012) Trial failure prompts soul-searching for critical-care specialists. *Nat Med* 18: 1000.
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 101: 1644–1655.
- Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, et al. (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. *Am J Respir Crit Care Med* 180: 640–648.
- Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, et al. (2011) Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. *Intensive Care Med* 37: 525–532.
- Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, et al. (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A* 110: 3507–3512.
- Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G (2013) Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. *Curr Opin Immunol*.
- Cook CH, Martin LC, Yenchar JK, Lahm MC, McGuinness B, et al. (2003) Occult herpes family viral infections are endemic in critically ill surgical patients. *Crit Care Med* 31: 1923–1929.
- Dockrell DH (2003) Human herpesvirus 6: molecular biology and clinical features. *J Med Microbiol* 52: 5–18.
- Chen Y, Bord E, Tompkins T, Miller J, Tan CS, et al. (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. *N Engl J Med* 361: 1067–1074.
- Chiche L, Forel JM, Papazian L (2011) The role of viruses in nosocomial pneumonia. *Curr Opin Infect Dis* 24: 152–156.
- Boothpur R, Brennan DC (2010) Human polyoma viruses and disease with emphasis on clinical BK and JC. *J Clin Virol* 47: 306–312.
- Bruynseels P, Jorens PG, Demey HE, Goossens H, Pattyn SR, et al. (2003) Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. *Lancet* 362: 1536–1541.
- Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, et al. (1999) Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. *Crit Care Med* 27: 1230–1251.
- Hotchkiss RS, Tinsley KW, Swanson PE, Schmiege RE Jr., Hui JJ, et al. (2001) Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. *J Immunol* 166: 6952–6963.

23. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, et al. (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. *JAMA* 306: 2594–2605.
24. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, et al. (2008) Cytomegalovirus reactivation in critically ill immunocompetent patients. *JAMA* 300: 413–422.
25. Kalil AC, Florescu DF (2009) Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. *Crit Care Med* 37: 2350–2358.
26. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, et al. (2001) Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. *Crit Care Med* 29: 541–547.
27. Linssen CF, Jacobs JA, Stelma FF, van Mook WN, Terporten P, et al. (2008) Herpes simplex virus load in bronchoalveolar lavage fluid is related to poor outcome in critically ill patients. *Intensive Care Med* 34: 2202–2209.
28. Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A, et al. (2007) Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. *Am J Respir Crit Care Med* 175: 935–942.
29. Touinssi M, Gallian P, Biagini P, Attoui H, Vialettes B, et al. (2001) TT virus infection: prevalence of elevated viraemia and arguments for the immune control of viral load. *J Clin Virol* 21: 135–141.
30. Shibayama T, Masuda G, Ajisawa A, Takahashi M, Nishizawa T, et al. (2001) Inverse relationship between the titre of TT virus DNA and the CD4 cell count in patients infected with HIV. *AIDS* 15: 563–570.
31. Focosi D, Maggi F, Albani M, Macera L, Ricci V, et al. (2010) Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. *J Clin Virol* 47: 189–192.
32. Bédard K, Dore-Nguyen M, Gagné MJ, Patey N, Brassard J, et al. (2014) Torque teno virus in children who underwent orthotopic liver transplantation: new insights about a common pathogen. *J Infect Dis* 209: 247–254.
33. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, et al. (2013) Temporal response of the human virome to immunosuppression and antiviral therapy. *Cell* 155: 1178–1187.
34. Sanchez JL, Storch GA (2002) Multiplex, quantitative, real-time PCR assay for cytomegalovirus and human DNA. *Journal of Clinical Microbiology* 40: 2381–2386.
35. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, et al. (2000) Association between clinical disease activity and Epstein-Barr virus reactivation in MS. *Neurology* 55: 178–184.
36. Espy MJ, Uhl JR, Mitchell PS, Thorvilson JN, Sven KA, et al. (2000) Diagnosis of herpes simplex virus infections in the clinical laboratory by LightCycler PCR. *Journal of Clinical Microbiology* 38: 795–799.
37. Maggi F, Pifferi M, Fornai C, Andreoli E, Tempestini E, et al. (2003) TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. *Journal of Virology* 77: 2418–2425.
38. Cheng XS, Bohl DL, Storch GA, Ryschewitsch C, Gaudreault-Keener M, et al. (2011) Inhibitory interactions between BK and JC virus among kidney transplant recipients. *Journal of the American Society of Nephrology* 22: 825–831.
39. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, et al. (2005) Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. *Am J Transplant* 5: 582–594.
40. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, et al. (2011) The late phase of sepsis is characterized by an increased microbiological burden and death rate. *Crit Care* 15: R183.
41. Micek ST, Welch EC, Khan J, Pervaz M, Doherty JA, et al. (2010) Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. *Antimicrob Agents Chemother* 54: 1742–1748.
42. De Vlieger G, Meersseman W, Lagrou K, Wouters P, Wilmer A, et al. (2012) Cytomegalovirus serostatus and outcome in nonimmunocompromised critically ill patients. *Crit Care Med* 40: 36–42.
43. Heininger A, Haeblerle H, Fischer I, Beck R, Riessen R, et al. (2011) Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. *Crit Care* 15: R77.
44. Kalil AC, Florescu DF (2011) Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis? *Crit Care* 15: 138.
45. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, et al. (2009) Increased circulating regulatory T cells (CD4(+)CD25(+)CD127(–)) contribute to lymphocyte anergy in septic shock patients. *Intensive Care Med* 35: 678–686.
46. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, et al. (2007) MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. *J Exp Med* 204: 1463–1474.
47. Humar A (2006) Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. *Transplantation* 82: S9–S14.
48. Juvonen E, Aalto S, Tarkkanen J, Volin L, Hedman K, et al. (2007) Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients. *Haematologica* 92: 819–825.
49. Gartner B, Preiksaitis JK (2010) EBV viral load detection in clinical virology. *J Clin Virol* 48: 82–90.
50. Wada K, Kubota N, Ito Y, Yagasaki H, Kato K, et al. (2007) Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay. *J Clin Microbiol* 45: 1426–1432.
51. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G (1998) High incidence of active cytomegalovirus infection among septic patients. *Clin Infect Dis* 26: 1076–1082.
52. Berrington WR, Jerome KR, Cook L, Wald A, Corey L, et al. (2009) Clinical correlates of herpes simplex virus viremia among hospitalized adults. *Clin Infect Dis* 49: 1295–1301.
53. Razonable RR, Fanning C, Brown RA, Espy MJ, Rivero A, et al. (2002) Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts. *J Infect Dis* 185: 110–113.
54. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, et al. (2006) Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. *JAMA* 296: 964–973.
55. Babel N, Volk HD, Reinke P (2011) BK polyomavirus infection and nephropathy: the virus-immune system interplay. *Nat Rev Nephrol* 7: 399–406.
56. Pollock JL, Presti RM, Pactzold S, Virgin HW (1997) Latent murine cytomegalovirus infection in macrophages. *Virology* 227: 168–179.
57. Prosch S, Wendt CE, Reinke P, Priemer C, Oppert M, et al. (2000) A novel link between stress and human cytomegalovirus (HCMV) infection: sympathetic hyperactivity stimulates HCMV activation. *Virology* 272: 357–365.
58. Hamprecht K, Steinmassl M, Einsele H, Jahn G (1998) Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection. *J Clin Virol* 11: 125–136.
59. Humar A, Michaels M, Monitoring AIWGoID (2006) American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *Am J Transplant* 6: 262–274.
60. Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, et al. (2007) Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. *Transplantation* 83: 433–438.
61. Beland K, Dore-Nguyen M, Gagne MJ, Patey N, Brassard J, et al. (2013) Torque Teno Virus in Children with Orthotopic Liver Transplantation: New Insights About a Common Pathogen. *J Infect Dis*.
62. Cook CH, Trgovcich J (2011) Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges. *Antiviral Res* 90: 151–159.
63. Wherry EJ, Day CL, Draenert R, Miller JD, Kiepiela P, et al. (2006) HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory. *Virology* 353: 366–373.
64. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, et al. (2007) Herpesvirus latency confers symbiotic protection from bacterial infection. *Nature* 447: 326–329.
65. Razonable RR (2013) Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. *Am J Transplant* 13 Suppl 3: 67–77; quiz 77–68.
66. Lee YJ, Chung D, Xiao K, Papadopoulos EB, Barker JN, et al. (2013) Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution. *Biol Blood Marrow Transplant* 19: 387–392.